Gout is the most common form of inflammatory arthritis caused by excess uric acid, with almost 10M patient diagnosed in the US alone. US patients are primarily treated with allopurinol, febuxostat (both are xanthine-oxidase inhibitors).
A large portion of the current market is well-controlled on generic allopurinol; however, there is still a sizeable market that are uncontrolled or unable to tolerate 1st line allopurinol that have an unmet need for a safe and effective agent.
Unmet medical need in under treated hyperuricemia associated with gout patients.
Large number of diagnosed, albeit untreated patients (9.8M); 30% (2.8M) are treated in the US:
• Of these, 50% (1.4M) are not well-controlled (uric acid >6 mg/dL) Treatment for Gout
• 1st line XOI drugs for Gout include allopurinol and to lesser extent febuxostat (black box warning)
• 12-35% (~1.6M) of diagnosed Gout patients have tophi; 0.16M are chronic refractory
• SAP-001 could be 1st line in this population